[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Frontier Medicines Corporation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":52},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100534895",false,"NCT06244771","A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors","An Open-Label, Phase 1\u002F2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors","PROSPER","Inclusion Criteria:\n\n* Histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumors with KRAS G12C mutation\n* Received and progressed or been intolerant to prior standard therapy OR standard therapy is considered inappropriate OR an investigational agent is considered standard of care\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Adequate hematological, renal, and hepatic function\n* Agrees not to participate in another interventional study while receiving study drug\n\nExclusion Criteria:\n\n* Leptomeningeal disease or carcinomatous meningitis\n* Clinically significant toxicity resulting from prior cancer therapies\n* Known or suspected hypersensitivity to FMC-376 or any components of the study drug\n* Condition that would interfere with study drug absorption\n* Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data","ALL","18 Years",{"count":19,"type":20},403,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.",[27,28,29,30,31,32,33,34],"Advanced Solid Tumors With KRAS G12C Mutations","Solid Tumor, Adult","Unresectable Solid Tumor","Metastatic Solid Tumor","Non Small Cell Lung Cancer","Colorectal Cancer","KRAS G12C","Pancreatic Cancer",[36,37,38],"Lung Cancer","KRAS","G12C","RECRUITING","2026-03-16",{"date":42,"type":43},"2026-03-18","ACTUAL",{"date":45,"type":43},"2024-02-12",{"date":47,"type":20},"2028-04",{"name":49,"class":50},"Frontier Medicines Corporation","INDUSTRY",26,""]